We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

BIOHIT Healthcare OY

Offers technologies and services for diagnosing and preventing gastrointestinal diseases and associated risks read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Biohit’s Innovative GastroPanel Quick Test Receives CE Mark

By LabMedica International staff writers
Posted on 15 Oct 2021
Print article
Image: GastroPanel Quick Test (Photo courtesy of Biohit Healthcare)
Image: GastroPanel Quick Test (Photo courtesy of Biohit Healthcare)

Biohit Healthcare’s (Helsinki, Finland) GastroPanel Quick Test, the latest innovation in its unique GastroPanel product family, is now CE marked.

The GastroPanel Quick Test is intended for diagnosing Helicobacter pylori infection and atrophic gastritis in patients with dyspeptic symptoms. The test measures pepsinogen I, pepsinogen II, gastrin-17 and antibodies against Helicobacter pylori from human plasma sample in one test. The test also identifies people at a risk of developing malignant cellular changes in stomach mucosa or who may require additional stomach examination or treatment. The test results are available in 20 minutes, enabling fast diagnosis and screening for further examinations.

The GastroPanel Quick Test system comprises of an immunological test and dedicated GP Reader device which interprets the result. The clinical performance of the GastroPanel quick test system is in line with the on market available and previously validated ELISA-based GastroPanel test. In a study, samples collected from 500 patients with upper abdominal symptoms were tested with the GastroPanel Quick Test. The results were compared with gastric endoscopies and biopsies performed according to international guidelines. The concordance between the methods was demonstrated to be excellent.

“We are excited to launch the GastroPanel Quick Test system with such excellent performance characteristics and fast turnaround time,” said Osmo Suovaniemi, the acting CEO of Biohit. “We believe that the test system will be well received by end users because the usability of the test system enables first-line diagnosis and screening of dyspeptic patients easier than ever before. We are eager to continue developing the testing system further. Next, we will extend the CE mark of the GastroPanel Quick Test to include finger-prick blood samples by the end of 2021.”

Related Links:
Biohit Healthcare

New
Gold Supplier
Vaginosis Test
VAGINAL PANEL REALTIME PCR KIT
New
β-hCG Test
RAMP TOTAL β-hCG Test
New
1,5-AG Test
1,5-Anhydroglucitol Test Kit
New
Allergen-Specific IgG/IgG4 Enzymimmunoassay
ALLERgen Specific IgG/IgG4 ELISA Kits

Print article
IIR Middle East

Channels

Technology

view channel
Image: OneDraw Blood Collection Device significantly reduces obstacles for drawing blood (Photo courtesy of Drawbridge Health)

Near Pain-Free Blood Collection Technology Enables High-Quality Testing

Blood tests help doctors diagnose diseases and conditions such as cancer, diabetes, anemia, and coronary heart disease, as well as evaluate organ functionality. They can also be used to identify disease... Read more

Industry

view channel
Image: The global infectious disease IVD market is expected to hit USD 57 billion by 2030 (Photo courtesy of Pexels)

Global Infectious Disease IVD Market Dominated by Molecular Diagnostics Technology

The global infectious disease in vitro diagnostics (IVD) market stood at USD 113.7 billion in 2021 and is expected to grow at a CAGR of -7.41% from 2022 to 2030 to hit around USD 56.89 billion by 2030,... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.